![Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2B Study at Clinical Trials on Alzheimer's Disease (CTAD) Conference](https://pharmashots.com/public/default-image/Press-Release-768x411.png )
Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2B Study at Clinical Trials on Alzheimer's Disease (CTAD) Conference
![](https://pharmashots.com/wp-content/uploads/2020/10/Press-Release-300x161.png)
Contacts
MEDIA CONTACT: Eisai Co., Ltd. Public Relations Department TEL: +81-(0)3-3817-5120 Eisai Inc. (U.S.) Libby Holman TEL: +1-201-753-1945 Libby_Holman@eisai.com INVESTOR CONTACT: Eisai Co., Ltd. Investor Relations Department TEL: +81-(0)70-8688-9685 |
MEDIA CONTACT: Biogen Inc. Ashleigh Koss +1-908-205-2572 public.affairs@biogen.com INVESTOR CONTACT: Biogen Inc. Mike Hencke +1-781-464-2442 IR@biogen.com |